Advisors Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.1M Sell
127,450
-27,803
-18% -$3.66M 0.25% 77
2026
Q1
$21.6M Sell
155,253
-7,370
-5% -$1.03M 0.36% 44
2025
Q4
$20M Sell
162,623
-7,634
-4% -$928K 0.34% 46
2025
Q3
$18.9M Sell
170,257
-35,774
-17% -$4.07M 0.32% 47
2025
Q2
$22.8M Sell
206,031
-33,903
-14% -$3.61M 0.41% 32
2025
Q1
$26.9M Buy
239,934
+14,358
+6% +$1.48M 0.51% 25
2024
Q4
$20.8M Sell
225,576
-29,260
-11% -$2.63M 0.38% 38
2024
Q3
$21.4M Sell
254,836
-18,896
-7% -$1.44M 0.39% 42
2024
Q2
$18.8M Buy
273,732
+11,232
+4% +$750K 0.37% 45
2024
Q1
$19.2M Sell
262,500
-11,718
-4% -$901K 0.37% 44
2023
Q4
$22.2M Sell
274,218
-42,521
-13% -$3.31M 0.45% 36
2023
Q3
$23.7M Sell
316,739
-3,397
-1% -$261K 0.51% 30
2023
Q2
$24.7M Sell
320,136
-27,918
-8% -$2.23M 0.5% 35
2023
Q1
$28.9M Buy
348,054
+45
+0% +$3.73K 0.59% 24
2022
Q4
$29.9M Buy
348,009
+25,863
+8% +$2.05M 0.62% 24
2022
Q3
$19.9M Buy
322,146
+18,525
+6% +$1.17M 0.42% 43
2022
Q2
$18.8M Buy
303,621
+34,453
+13% +$2.13M 0.36% 52
2022
Q1
$16M Buy
269,168
+19,875
+8% +$1.27M 0.25% 77
2021
Q4
$18.1M Buy
249,293
+20,186
+9% +$1.39M 0.26% 69
2021
Q3
$16M Buy
229,107
+14,808
+7% +$1.04M 0.24% 75
2021
Q2
$14.8M Buy
214,299
+28,290
+15% +$1.89M 0.22% 80
2021
Q1
$12M Buy
186,009
+4,393
+2% +$283K 0.19% 106
2020
Q4
$10.6M Sell
181,616
-2,408
-1% -$145K 0.18% 110
2020
Q3
$11.6M Sell
184,024
-18,903
-9% -$1.31M 0.22% 88
2020
Q2
$15.6M Sell
202,927
-25,397
-11% -$1.95M 0.3% 60
2020
Q1
$17.1M Sell
228,324
-25,411
-10% -$1.76M 0.41% 46
2019
Q4
$16.5M Buy
253,735
+29,197
+13% +$1.9M 0.29% 76
2019
Q3
$14.2M Buy
224,538
+27,824
+14% +$1.82M 0.26% 83
2019
Q2
$13.3M Buy
196,714
+44,964
+30% +$2.96M 0.24% 90
2019
Q1
$9.87M Buy
151,750
+60,575
+66% +$4.03M 0.18% 133
2018
Q4
$5.7M Buy
91,175
+28,507
+45% +$1.99M 0.11% 210
2018
Q3
$4.84M Sell
62,668
-57,510
-48% -$4.34M 0.08% 302
2018
Q2
$8.51M Sell
120,178
-68,766
-36% -$4.86M 0.14% 170
2018
Q1
$14.9M Sell
188,944
-3,546
-2% -$282K 0.25% 96
2017
Q4
$13.8M Buy
192,490
+720
+0.4% +$54.7K 0.23% 109
2017
Q3
$15.5M Buy
191,770
+29,118
+18% +$2.23M 0.26% 91
2017
Q2
$11.5M Buy
162,652
+74,350
+84% +$4.95M 0.19% 128
2017
Q1
$6M Buy
88,302
+30,933
+54% +$2.18M 0.1% 274
2016
Q4
$4.11M Sell
57,369
-6,504
-10% -$483K 0.07% 393
2016
Q3
$5.05M Sell
63,873
-6,647
-9% -$540K 0.08% 347
2016
Q2
$5.88M Buy
70,520
+108
+0.2% +$9.59K 0.1% 312
2016
Q1
$6.47M Sell
70,412
-1,667
-2% -$150K 0.11% 269
2015
Q4
$7.29M Buy
72,079
+1,985
+3% +$207K 0.12% 249
2015
Q3
$6.88M Buy
70,094
+1,581
+2% +$176K 0.11% 268
2015
Q2
$8.02M Buy
68,513
+5,666
+9% +$619K 0.11% 252
2015
Q1
$6.17M Buy
62,847
+1,781
+3% +$181K 0.08% 306
2014
Q4
$5.76M Buy
61,066
+3,874
+7% +$401K 0.08% 311
2014
Q3
$6.09M Sell
57,192
-1,701
-3% -$167K 0.08% 295
2014
Q2
$4.88M Buy
58,893
+3,995
+7% +$311K 0.07% 344
2014
Q1
$3.89M Buy
54,898
+6,346
+13% +$498K 0.06% 372
2013
Q4
$3.65M Buy
48,552
+3,121
+7% +$217K 0.06% 382
2013
Q3
$2.85M Buy
45,431
+4,082
+10% +$244K 0.05% 408
2013
Q2
$2.12M Buy
+41,349
New +$2.16M 0.04% 449

Other funds holding GILD

Advisors Asset Management's GILD Position: Q2 2026 in Review

Advisors Asset Management reduced its Gilead Sciences (GILD) stake by 18% in Q2 2026, selling an estimated $3.66M and leaving 127,450 shares worth $16.1M. The position accounts for 0.25% of the portfolio, ranked #77.

Advisors Asset Management first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $29.9M in Q4 2022. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Advisors Asset Management held 127,450 shares of Gilead Sciences worth $16.1M as of Q2 2026.
  • Advisors Asset Management sold 27,803 Gilead Sciences shares in Q2 2026, an estimated $3.66M.
  • Gilead Sciences made up 0.25% of Advisors Asset Management's portfolio in Q2 2026, its #77 holding.
  • Advisors Asset Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Advisors Asset Management's Gilead Sciences position peaked at $29.9M in Q4 2022.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.